Viewing data from:

THYROGEN

BLA

THYROTROPIN ALFA | B020898 | GENZYME

Biologic LOENo LOE data

No exclusivity dates or listed patents found in Purple Book

Purple Book Patents

No listed patents in Purple Book.

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

No ANDA patent litigation cases (NOS 835) matched from PACER

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

No clinical trials found on ClinicalTrials.gov for this drug

Medicare Part B Spending

CMS physician-administered drug spending for Thyrogen (2024)

Total Spending

$12.3M

Total Claims

4,912

Beneficiaries

2,930

ASP Price

$2045.68

Spending Trend

$10.7M(2020)→$11.0M(2021)→$12.0M(2022)→$12.1M(2023)→$12.3M(2024)

YoY Change:+3.5%

5yr CAGR:+6.7%

HCPCS: J3240 — Injection, thyrotropin alpha, 0.9 mg, provided in 1.1 mg vial

Source: CMS Medicare Part B Spending by Drug (2024). Shows physician-administered drug costs.

Approval Letters

10 letters from Drugs@FDA

Source: Drugs@FDA application documents.

Products (1)

#001 — 1.1MG/VIAL

▴

INJECTABLE;INJECTION | Approved: 1998-11-30 00:00:00

No patent or exclusivity listings for this strength.